2025
Validity of Diagnostic Codes and Laboratory Tests to Identify Cholangiocarcinoma and Its Subtypes
Ferrante N, Hubbard R, Weinfurtner K, Mezina A, Newcomb C, Furth E, Bhattacharya D, Njei B, Taddei T, Singal A, Hoteit M, Park L, Kaplan D, Re V. Validity of Diagnostic Codes and Laboratory Tests to Identify Cholangiocarcinoma and Its Subtypes. Pharmacoepidemiology And Drug Safety 2025, 34: e70154. PMID: 40328444, PMCID: PMC12055315, DOI: 10.1002/pds.70154.Peer-Reviewed Original ResearchMeSH KeywordsAgedAlgorithmsBile Duct NeoplasmsCholangiocarcinomaFemaleHumansInternational Classification of DiseasesMaleMiddle AgedPharmacoepidemiologyPredictive Value of TestsReproducibility of ResultsRetrospective StudiesUnited StatesUnited States Department of Veterans AffairsConceptsPositive predictive valueVeterans Health AdministrationExtrahepatic cholangiocarcinomaValidity of diagnostic codesInternational Classification of Diseases for OncologyUS Veterans Health AdministrationConfidence intervalsPharmacoepidemiological studiesICD-O-3Days of diagnosisVA dataHealth AdministrationIntrahepatic cholangiocarcinomaDiagnostic codesHistology codesCholangiocarcinomaUnique patientsInclusion criteriaCholangiocarcinoma subtypesTopography codesPredictive valuePatientsEvaluate medicationsSubtypesEvaluate determinantsMortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study
Njei B, Mezzacappa C, John B, Serper M, Kaplan D, Taddei T, Mahmud N. Mortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study. Digestive Diseases And Sciences 2025, 70: 802-813. PMID: 39779587, PMCID: PMC11839701, DOI: 10.1007/s10620-024-08764-4.Peer-Reviewed Original ResearchMeSH KeywordsAgedBody Mass IndexCardiovascular DiseasesCohort StudiesFatty LiverFemaleHumansLiver CirrhosisMaleMiddle AgedRetrospective StudiesThinnessUnited StatesUnited States Department of Veterans AffairsConceptsNon-lean individualsAll-cause mortalityMajor adverse cardiovascular eventsIncreased risk of all-cause mortalityRisk of all-cause mortalityVeterans Health AdministrationRisk of hepatic decompensationPrevalence of diabetesRisk of cardiovascular mortalityHepatic decompensationHigher mortality riskCardiovascular-related mortalityCox proportional hazards modelsCohort study of patientsCardiovascular outcomesIncident major adverse cardiovascular eventsRetrospective cohort study of patientsProportional hazards modelNon-HispanicRetrospective cohort studyCompeting risk regressionHealth AdministrationMultivariate Cox proportional hazards modelLean individualsAssessed associations
2024
Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status
Re V, Newcomb C, Carbonari D, Mezochow A, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Torgersen J. Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status. Pharmacoepidemiology And Drug Safety 2024, 33: e70069. PMID: 39662972, PMCID: PMC11634562, DOI: 10.1002/pds.70069.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedChemical and Drug Induced Liver InjuryChronic DiseaseCohort StudiesFemaleHospitalizationHumansLiver DiseasesMaleMiddle AgedPharmacoepidemiologyProton Pump InhibitorsUnited StatesUnited States Department of Veterans AffairsConceptsProton pump inhibitor initiationHazard ratioVeterans Health AdministrationSevere acute liver injuryProton pump inhibitorsChronic liver diseaseAcute liver injuryRates of hospitalizationSafety of medicationsPPI initiativesHealth AdministrationLiver disease statusMedication exposurePharmacoepidemiological studiesMedicationConfoundingScoresReports of hepatotoxicityDisease statusHepatotoxic medicationsDrug exposurePump inhibitorsHepatotoxic drugsOutpatient initiationHepatic safety
2019
Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus
Njei B, Esserman D, Krishnan S, Ohl M, Tate JP, Hauser RG, Taddei T, Lim J, Justice AC. Regional and Rural-Urban Differences in the Use of Direct-acting Antiviral Agents for Hepatitis C Virus. Medical Care 2019, 57: 279-285. PMID: 30807449, PMCID: PMC6436819, DOI: 10.1097/mlr.0000000000001071.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntiviral AgentsFemaleHepacivirusHepatitis CHumansMaleRural PopulationUnited StatesUnited States Department of Veterans AffairsUrban PopulationVeteransConceptsDirect-acting antiviral agentsHepatitis C virus infectionVeterans Affairs Healthcare SystemRural-Urban Commuting Area codesCurative HCV treatmentRural-urban designationC virus infectionElectronic health record dataHepatitis C virusPrior treatment experienceLower odds ratioHealth record dataZone improvement plan codeEligible patientsHCV treatmentAntiretroviral medicationsRural-urban residenceLiver diseaseUnadjusted analysesC virusRural-urban differencesOdds ratioMultivariable modelLower incidenceObservational study
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply